Our results are in line with studies in several other tumor forms, including malignant melanoma and cancers of the breast, prostate, endometrium, stomach, and liver, where increased EZH2 expression has been linked to more aggressive tumor behaviour and poor prognosis [7,9,17,36,37]. This evidence concerns the gene EZH2 and cancer.